Fortis Frontier Plc · LSE:FORF
Fortis Frontier — MyHealthChecked — FY2022 Earnings Presentation
26 slides from Fortis Frontier's earnings presentation, Apr 3, 2023
Slide 1: MyHealthChecked Plc Preliminary Results for the year ended 31 December 2022
MyHealthChecked Plc Preliminary Results for the year ended 31 December 2022 3rd April 2023 Penny McCormick, CEO Nick Edwards, CFO Adam Reynolds, Chairman
Slide 2: Disclaimer
Disclaimer Document information The content of this Presentation has not been reviewed, authorised or otherwise approved by the UK Financial Conduct Authority (FCA) or any other regulatory body. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an indivi
Slide 3: Presenting today
Presenting today o 15 years in commercial leadership in o Skilled FD and growth-driven Analyst Penny McCormick medical devices plus IVD Nick Edwards o 30 years' experience within multiple o Commercial out licensing to £32m commercial organisations, cross- Chief Executive Officer Chief Financial Offi
Slide 4: Appendix: A knowledgeable and diverse Non-Exec Board
Appendix: A knowledgeable and diverse Non-Exec Board Adam Reynolds Lesley Innes Neil Mesher Lyn Rees Chairman Non-Exec Director Non-Exec Director Non-Exec Director Chairman, investor and NED Public and private company Philips Senior Vice President W. CEO of Yourgene Health. portfolio past and presen
Slide 5: MHC performance overview
MHC performance overview 4 5 6 Second consecutive year of strong growth and profitability Soft launch of initial DNA at- Investment in new B2B2C customer home wellness portfolio in product pipeline and relationships developed in July 2022 digital healthcare- preparation for nationwide centric techno
Slide 6: Financial highlights: 2nd consecutive year of strong revenue growth and profitability
Financial highlights: 2nd consecutive year of strong revenue growth and profitability Record revenues and cash position Significant revenue growth Adjusted EBITDA* of £2.3m up 36% to £22.3m (2021: £2.7m) – reflecting (2021: £16.4m) transition of product mix from PCR testing to distribution of LFTs G
Slide 7: Commercial & Operational highlights
Commercial & Operational highlights Building on agreements with: >17m tests 2300 2300stores stores 10m Advantage 10m Advantage 1400 stores Distribution of Over 17.3m tests Soft launch of initial Card Cardholders holders FlowFlex™ lateral flow delivered into the DNA tests portfolio kits into top phar
Slide 8: Our vision is to deliver a trusted, compliant digital platform
Our vision is to deliver a trusted, compliant digital platform, that tailors B2B services to optimise individuals’ health, so that customers can uniquely benefit from a long- lasting relationship with their test provider • Giving accessibility and autonomy through self-select testing • Empowering cu
Slide 9: MHC well placed to deliver responsively to market trends
MHC well placed to deliver responsively to market trends Hardman & Co* flag well-reported trends that they believe will continue to drive growth in the clinical laboratory service industry over the medium and long term: 4. Precision 1. Demographics 2. Outsourcing 3. Lifestyle medicine Trends include
Slide 10: The need: Executing a successful business model
The need: Executing a successful business model Pioneering a Best in class customer-first through our Responsive and approach for By being…. providing valued sustainable innovation in platform, customer and healthier Progressive in products service for futures Providing a health our thinking and and
Slide 11: Spring 2023: Extensive range of self tests and lab analysed
Spring 2023: Extensive range of self tests and lab analysed
Slide 12: Unique range of DNA, blood and urine biomarker tests across multiple health areas
Unique range of DNA, blood and urine biomarker tests across multiple health areas Men’s Women’s Cardiovascular Weight Nutritional General Health Health Health Management Health wellbeing 6 initial screening tests 14 blood analysis tests 5 DNA analysis tests
Slide 13: A unique journey through test types for different needs
A unique journey through test types for different needs Initial screening tests Blood analysis tests DNA analysis tests “I want to know if a vitamin deficiency might “I want to get an in depth analysis of my “Since learning of my deficiency, I want to vitamin & mineral levels and advice on how to ma
Slide 14: We're investing in our "growth" stack, not a "tech" stack
We’re investing in our "growth" stack, not a "tech" stack Which focuses on development on the post purchase journey –retention and advocacy Our platform is being developed to be highly scalable and versatile – meeting Connected care – chat, identified customer needs and video consultation Custom adv
Slide 15: How we will build on 2022: investment in commercialisation
How we will build on 2022: investment in commercialisation Solidifying our brand, Amplified with alignment Growing our digital MD reviewed content & Digital investment: Focus tone of voice and to increased UK exposure & adopting advice that translates on CRM communication strategy distribution, grow
Slide 16: MyHealthChecked key take-aways
MyHealthChecked key take-aways Revenue up 36% to £22.3m We remain proactive in our Strong cash position to ensure the Company is self funded for the next evaluation of attractive earnings growth phases enhancing M&A targets that will accelerate our growth plans Building onwards from retail’s Covid s
Slide 17: Nutrition is the foundation of good health
nutrition is the foundation of good health. good health is the foundation of everything else. Ready for a healthier you?
Slide 18: Appendix
To receive Company updates and information about investor events, contact MyHealthChecked@walbrookpr.com Appendix
Slide 19: Consolidated statement of comprehensive income
Appendix Consolidated statement of comprehensive income For the year ended 31 December 2022 Operating profit Profit before income tax Profit for the year Attributable to owners of the parent
Slide 20: Consolidated statement of financial position
Appendix Consolidated statement of financial position For the year ended 31 December 2022 Total non-current assets Total current assets Total assets Total current liabilities Total non-current liabilities Total liabilities Net Assets Total equity
Slide 21: Consolidated statement of cash flows
Appendix Consolidated statement of cash flows For the year ended 31 December 2022 Adjusted operating profit before changes in working capital Cash generated in operations Net cash inflow from operating activities Net cash flows used in investing activities Net cash flows from Net change in cash and
Slide 22: Shareholder information
Appendix Shareholder information Mercia Investment Plan LP* 26.38% 205.8M Market CAP Directors share holding 1.93% 15.0M £8.19M Remaining Shares 71.69% 559.3M 780.1M ISSUED SHARES *Together with Mercia (General Partner) Limited and Finance Yorkshire Limited and Pershing Nominees Limited total holdin
Slide 23: Establishing a strong foothold in the UK wellness industry
Establishing a strong foothold in the UK wellness industry Apr 2021 Aug 2021 Nov 2021 Jun 2022 July 2022 Boots contract Lloyds DNA Wellness COVID lateral Launched DNA #1 and launch contract Portfolio flow tests in- Wellness on F2F launched store at Boots Amazon HQ relocation Covid test CFO Nick To C
Slide 24: Appendix 1. MyHealthChecked at-home genetic panel: DNA tests
Appendix 1. MyHealthChecked at-home genetic panel: DNA tests We offer easy, accurate and reliable DNA home test kits for heart health, intolerances, vitamins and minerals, weight management and glucose management Our DNA tests can offer a ‘glimpse’ into the future, helping identify potential issues
Slide 25: Appendix 2. Essential blood tests: Blood kits
Appendix 2. We offer essential blood tests providing a health insights, conveniently: Blood kits We are bringing to market a range of capillary blood sampling that covers everything from heart, liver, kidney, and glucose through to thyroid health Our lab partner provides bespoke service that draws u
Slide 26: Appendix 3. Lateral flow tests for wellness and surveillance
Appendix 3. We provide lateral flow tests as part of wellness or what we call 'surveillance’ The Wellness lateral flow test is a quick self-test that provides qualitative indications of your health status with results in minutes It determines whether or not the amount of certain biomarker in the sam